Alternative complement pathway hemolytic assays reveal incomplete complement blockade in patients treated with eculizumab.

[1]  A. Blancher,et al.  A microplate assay to measure classical and alternative complement activity , 2017, Clinical chemistry and laboratory medicine.

[2]  D. Ricklin,et al.  Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. , 2017, Blood.

[3]  B. Tönshoff,et al.  Monitoring of complement activation biomarkers and eculizumab in complement‐mediated renal disorders , 2017, Clinical and experimental immunology.

[4]  Hans Elmlund,et al.  Structural basis for therapeutic inhibition of complement C5 , 2016, Nature Structural &Molecular Biology.

[5]  J. Wetzels,et al.  Sensitive, reliable and easy-performed laboratory monitoring of eculizumab therapy in atypical hemolytic uremic syndrome. , 2015, Clinical immunology.

[6]  V. Gouilleux-Gruart,et al.  Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule , 2015, mAbs.

[7]  E. Volokhina,et al.  Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivo. , 2015, Blood.

[8]  J. Andersen,et al.  Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. , 2015, Immunobiology.

[9]  R. Porcher,et al.  Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. , 2015, Blood.

[10]  Francesco Tedesco,et al.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. , 2014, Blood.

[11]  G. Ardissino,et al.  Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome , 2014, Journal of thrombosis and haemostasis : JTH.

[12]  G. Remuzzi,et al.  Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. , 2013, The New England journal of medicine.

[13]  E. Conway,et al.  Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway. , 2012, Blood.

[14]  S. Wigmore,et al.  Clinical Practice Guidelines for the management of atypical Haemolytic Uraemic Syndrome in the United Kingdom , 2010, British journal of haematology.

[15]  John D Lambris,et al.  Generation of C5a in the absence of C3: a new complement activation pathway , 2006, Nature Medicine.

[16]  K. Joiner,et al.  A study of optimal reaction conditions for an assay of the human alternative complement pathway. , 1983, American journal of clinical pathology.